Tech Company Financing Transactions
Gate Bioscience Funding Round
Gate Bioscience closed a $60 million Series A investment round on 11/1/2023. Investors included Versant Ventures, Andreessen Horowitz and Arch Venture Partners.
Transaction Overview
Company Name
Announced On
11/1/2023
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to expand operations and its development efforts.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2000 Sierra Point Parkway 200
Brisbane, CA 94005
USA
Brisbane, CA 94005
USA
Phone
Undisclosed
Website
Email Address
Overview
Developer of small molecule drugs intended to selectively eliminate harmful extracellular proteins at their origin, inside cells, and prevent them from emerging to cause disease. The company combines a privileged library of molecular gates, a suite of bespoke secretion-focused assays and technologies, and deep expertise in the biology of the secretory pathway to enable precise, rapid, and repeatable drug discovery, enabling doctors to address a wide range of diseases with a single therapeutic mechanism.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jordi Fink
Chief Scientific Officer
Brian Cathers
Chief Technical Officer
Raman Talwar
Browse more venture capital transactions:
Prev: 11/1/2023: CModel Data venture capital transaction
Next: 11/1/2023: Jona venture capital transaction
Share this article
Where The Data Comes From
We record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs